SLC5A2 and Hypoglycemia: New hypoglycemic drugs that emerged in recent years, such as SGLT2 inhibitors and GLP-1 receptor agonists, have relatively few hypoglycemic events, but in the process of hypoglycemia, there is cardiovascular protection [53].